



BREZTRI
AEROSPHERE®

(budesonide 160 mcg, glycopyrrolate
9/18 mcg and formoterol fumarate
4.8 mcg) Inhalation Aerosol

You're Invited!

Two Conditions, One Triple Therapy: BREZTRI

Join us for an educational program hosted by AstraZeneca,
exploring the clinical impact of COPD and asthma and
reviewing the latest evidence for BREZTRI in both conditions.



Program Details

Date & Time

August 11, 2026
06:30 PM – 07:30 PM
Central Daylight Time

Location

Perry's Steakhouse and Grille
4 Perimeter Park South
Birmingham, AL 35243

Presented By

Haley Hoy
Acute Care Nurse Practitioner/ Transplant Coordinator
Vanderbilt University

To find out more or to register, please contact:

Karen Sykes
(205) 7902106
BY: 8/8/2026

Indications

BREZTRI AEROSPHERE
160 mcg/9 mcg/4.8 mcg is
indicated for the maintenance
treatment of chronic
obstructive pulmonary disease
(COPD) in adult patients.

BREZTRI AEROSPHERE
160 mcg/18 mcg/4.8 mcg is
indicated for the maintenance
treatment of asthma in adult
and pediatric patients 12 years
of age and older.

Limitations of use

Not indicated for the relief of
acute bronchospasm.

IMPORTANT SAFETY INFORMATION

- » BREZTRI is contraindicated:
 - » For the primary treatment of status asthmaticus or other acute episodes of asthma or COPD requiring intensive measures
 - » In patients who have a hypersensitivity to budesonide, glycopyrrolate, formoterol fumarate or product excipients
- » Long-acting beta₂-adrenergic agonist (LABA) monotherapy for asthma is associated with an increased risk of serious asthma-related events. These findings are considered a class effect of LABA monotherapy. When a LABA is used in a fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS use alone. Available data do not suggest an increased risk of death with use of LABA in patients with COPD

Please see additional Important Safety Information on reverse and accompanying full Prescribing Information, including Patient Information and Instructions for Use.

PhRMA Guidance: This event is conducted in accordance with the PhRMA Code on Interactions with Healthcare Professionals and is limited to healthcare professionals with an educational need for the information being presented. Attendees are expected to stay for the entire duration of the presentation. Repeat attendance at a Speaker Program on the same or substantially the same topic is generally not appropriate unless the attendee has a legitimate educational need to attend. Attendance by guests or spouses is generally not appropriate. AstraZeneca will not pay for or provide alcohol in connection with our Speaker Programs.

State and Federal Laws: Certain states and federal agencies have defined the maximum fair market value allowable for modest meals given to healthcare professionals or prohibited the receipt of meals at company-sponsored events. You are accountable for understanding such restrictions and complying with them. If you are impacted by those restrictions, we respectfully request that you not partake in the meal offered by AstraZeneca at the event. Please ask the AstraZeneca representative at the event for information about purchasing food at the event.

Disclosure by AstraZeneca: Subject to federal and state regulations, AstraZeneca will disclose information related to meals provided to attendees, which will be made public. To ensure accurate transparency in the reporting of meals, AstraZeneca requires program attendees to sign in upon arrival and indicate if a meal was accepted.

ICS, inhaled corticosteroid; PhRMA, Pharmaceutical Research and Manufacturers of America.

BREZTRI AEROSPHERE is a registered trademark of the AstraZeneca group of companies.

©2026 AstraZeneca. All rights reserved. US-113633 6/26



IMPORTANT SAFETY INFORMATION (cont'd)

- » BREZTRI should not be initiated in patients with acutely deteriorating COPD or asthma, which may be a life-threatening condition
- » BREZTRI is NOT a rescue inhaler. Do NOT use to relieve acute symptoms; treat with an inhaled short-acting beta₂-agonist
- » BREZTRI should not be used more often than recommended; at higher doses than recommended; or in combination with LABA-containing medicines, due to risk of overdose. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs
- » Oropharyngeal candidiasis has occurred in patients treated with orally inhaled drug products containing budesonide. Advise patients to rinse their mouths with water without swallowing after inhalation
- » Lower respiratory tract infections, including pneumonia, have been reported following ICS. Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of pneumonia and exacerbations frequently overlap
- » Due to possible immunosuppression, potential worsening of infections could occur. Use with caution. A more serious or fatal course of chickenpox or measles can occur in susceptible patients
- » Particular care is needed for patients transferred from systemic corticosteroids to ICS because deaths due to adrenal insufficiency have occurred in patients during and after transfer. Taper patients slowly from systemic corticosteroids if transferring to BREZTRI
- » Hypercorticism and adrenal suppression may occur with regular or very high dosage in susceptible individuals. If such changes occur, consider appropriate therapy
- » Caution should be exercised when considering the coadministration of BREZTRI with long-term ketoconazole and other known strong CYP3A4 Inhibitors. Adverse effects related to increased systemic exposure to budesonide may occur
- » If paradoxical bronchospasm occurs, discontinue BREZTRI immediately and institute alternative therapy
- » Anaphylaxis and other hypersensitivity reactions (eg, angioedema, urticaria or rash) have been reported. Discontinue and consider alternative therapy
- » Use caution in patients with cardiovascular disorders, especially coronary insufficiency, as formoterol fumarate can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles
- » Decreases in bone mineral density have been observed with long-term administration of ICS. Assess initially and periodically thereafter in patients at high risk for decreased bone mineral content
- » Monitor growth in pediatric patients
- » Glaucoma and cataracts may occur with long-term use of ICS. Worsening of narrow-angle glaucoma may occur, so use with caution. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use BREZTRI long term. Instruct patients to contact a healthcare provider immediately if symptoms occur
- » Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to contact a healthcare provider immediately if symptoms occur
- » Use caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis or unusually responsive to sympathomimetic amines
- » Be alert to hypokalemia or hyperglycemia
- » Most common adverse reactions (incidence $\geq 2\%$) are:
 - » **COPD:** upper respiratory tract infection, pneumonia, back pain, oral candidiasis, influenza, muscle spasms, urinary tract infection, cough, sinusitis, and diarrhea
 - » **Asthma:** nasopharyngitis, pneumonia, and headache
- » BREZTRI should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors and tricyclic antidepressants, as these may potentiate the effect of formoterol fumarate on the cardiovascular system
- » BREZTRI should be administered with caution to patients being treated with:
 - » Strong cytochrome P450 3A4 inhibitors (may cause systemic corticosteroid effects)
 - » Adrenergic drugs (may potentiate effects of formoterol fumarate)
 - » Xanthine derivatives, steroids, or non-potassium sparing diuretics (may potentiate hypokalemia and/or ECG changes)
 - » Beta-blockers (may block bronchodilatory effects of beta-agonists and produce severe bronchospasm)
 - » Anticholinergic-containing drugs (may interact additively). Avoid use with BREZTRI
- » Use BREZTRI with caution in patients with hepatic impairment, as budesonide and formoterol fumarate systemic exposure may increase. Patients with severe hepatic disease should be closely monitored

Please see accompanying full Prescribing Information, including Patient Information and Instructions for Use.

You are encouraged to report negative side effects of AstraZeneca prescription drugs by calling 1-800-236-9933. If you prefer to report these to the FDA, call 1-800-FDA-1088.



BREZTRI
AEROSPHERE®

(budesonide 160 mcg, glycopyrrolate
9/18 mcg and formoterol fumarate
4.8 mcg) Inhalation Aerosol

AstraZeneca

BREZTRI AEROSPHERE is a registered trademark of the AstraZeneca group of companies.
©2026 AstraZeneca. All rights reserved. US-113633 6/26